Arti­va boasts ear­ly NK cell ther­a­py re­sults, giv­ing life­line to part­ner Af­fimed

3 years ago
R&D

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

3 years ago
R&D
Cell/Gene Tx

Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

3 years ago
Financing
Startups

EMA rec­om­mends re­vok­ing au­tho­riza­tion of No­var­tis' sick­le cell drug

3 years ago
Pharma

As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

3 years ago
R&D

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

3 years ago
Financing
Startups

Bris­tol My­ers de­tails PhI­II win in first-line test of Re­blozyl for re­duc­ing trans­fu­sions in ear­ly blood can­cer ...

3 years ago
R&D

Stephen Hahn’s can­cer-test­ing biotech hires a new CMO; For­mer Io­vance ex­ec named CEO of Ob­sid­i­an

3 years ago
Peer Review

Janssen re­ports de­cline in 2022 net prices as out-of-pock­et costs grow

3 years ago
Pharma

Mir­ror­ing Sen­ate coun­ter­parts, House com­mit­tee ad­vances PBM re­forms

3 years ago
Pharma

In 2023, FDA ap­proves far few­er first gener­ic drugs than in re­cent years

3 years ago
FDA+

Gilead adds more pa­tient rep­re­sen­ta­tion in next phase of HIV med Bik­tarvy cam­paign

3 years ago
Pharma
Marketing

Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

3 years ago
Deals
Pharma

Il­lu­mi­na chair­man oust­ed from board as ac­tivist in­vestor Ic­ahn wins par­tial vic­to­ry

3 years ago
People

Bi­par­ti­san law­mak­ers pres­sure FDA on com­mon chemother­a­pies now in short­age

3 years ago
Pharma
Manufacturing

Ab­Cellera and Cana­da to in­vest $500M+ to boost an­ti­body man­u­fac­tur­ing and re­search

3 years ago
Financing
Discovery

Man­u­fac­tur­ing roundup: Ther­mo Fish­er opens fa­cil­i­ty in Sin­ga­pore; Forge Bi­o­log­ics to part­ner with con­sor­tium to ...

3 years ago
Manufacturing

DNA man­u­fac­tur­er Touch­light ex­pands its cam­pus to Vic­to­ri­an-era wa­ter­works build­ing

3 years ago
Manufacturing

Rich Hor­gan spear­head­ed a gene ther­a­py for his broth­er. The tri­al end­ed in tragedy, but the work con­tin­ues for more ...

3 years ago
Cell/Gene Tx
In Focus

More than a year af­ter its emer­gency au­tho­riza­tion, FDA ful­ly ap­proves Pfiz­er's Covid pill Paxlovid for adults

3 years ago
FDA+
Coronavirus

BioX­cel looks to ex­pand la­bel to at-home use for lead psych drug. Ini­tial da­ta are mixed

3 years ago
R&D

Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

3 years ago
R&D
Pharma

Apel­lis re­ports PhII ALS fail af­ter stop­ping open-la­bel ex­ten­sion in April

3 years ago
R&D

Boehringer In­gel­heim ex­tends 2020 col­lab with Ox­ford Bio­Ther­a­peu­tics; Eu­ro­pean biotechs claim pos­i­tive PhI I/O da­ta

3 years ago
News Briefing
First page Previous page 336337338339340341342 Next page Last page
A service from the Financial Times